Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
AnGes. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
AnGes's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AnGes has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare AnGes's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare AnGes's earnings growth to the Germany market average as no estimate data is available.
Unable to compare AnGes's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if AnGes is high growth as no earnings estimate data is available.
Unable to determine if AnGes is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
AnGes's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Ei Yamada, Ph.D. has been the President and Chief Executive Officer of AnGes MG Inc since September 2002. Mr. Yamada has been the Chief Executive Officer at AnGes Euro Limited since June 2002 and AnGes Inc. since October 2003. He served as General Manager of Business Development of AnGes MG, Inc. since May 2001. Previously, he served with companies including Mitsubishi Chemical Corp., since April 1982, Sosei K.K. since January 1995 and Takara Shuzo Co., Ltd. since August 2000. He has been a Director of AnGes MG, Inc. since August 2001. He serves as a Director of Dragon Genomics Inc. and ImmunoFrontier, Inc. He was a Research Scientist at the Japan Society for the Promotion of Science under a promotion program. Mr. Yamada completed his studies in Medicine from Tohoku University.
Insufficient data for Ei to compare compensation growth.
Insufficient data for Ei to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the AnGes board of directors is about average.
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. The company’s lead product is HGF Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. It also offers Naglazyme, a drug for the treatment of mucopolysaccharidosis VI, an intractable disease in Japan. In addition, the company is developing NF?B Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan; and SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases. It also has alliances with Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and co-development agreement with Vasomune Therapeutics for the development and commercialization of therapeutics treating diseases associated with blood vessel dysfunction and destabilization. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.